Novartis' Beovu recommended by NICE
Swiss pharma giant Novartis (NOVN: VX) has announced that the UK's - National Institute for Health and Care Excellence (NICE) recommends Beovu (brolucizumab) as a treatment option on the National Health Service (NHS) in England for a leading cause of visual impairment due to diabetic macular oedema (DMO) in adults.
The NICE's review was completed in just over five months using its new expedited fast-track cost comparison appraisal process. The decision is based on evidence from the Phase III KESTREL and KITE trials investigating Beovu versus aflibercept, the currently approved treatment.
These trials were the first to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu could be administered less frequently versus aflibercept, a drug which is sold under the brand names Eylea and Zaltrap by Regeneron Pharmaceuticals (Nasdaq: REGN) and Bayer (BAYN: DE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze